Fairvalue-Calculator Fairvalue-Calculator
EN DE

Chiron Real Estate Inc (XRN) Fair Value & Analysis

Real Estate · US · Market cap $473M

Price$36.12
Fair Value$90.04
Upside+149.3%
Quality93/100
Evidence: Medium Range $55.23 – $90.04

Fair value as of: Jun 25, 2026

Analysis

Chiron Real Estate Inc (XRN) currently trades at $36.12, while our model-based Fair Value estimate is $90.04 — implying the stock looks roughly 149.3% undervalued today. We read business quality at 93/100 (high quality), in the Real Estate sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Chiron Real Estate Inc. is a net-lease medical REIT that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. Chiron Real Estate Inc. was established on March 18, 2011, incorporated in Maryland and is based in Bethesda, Maryland.

Open the full interactive analysis →

Similar stocks

Welltower Inc (WELL) -77% Ventas, Inc (VTR) -79% Omega Healthcare Investors, Inc (OHI) -11% Healthpeak Properties, Inc (DOC) -82% American Healthcare REIT, Inc (AHR) -78% CareTrust REIT, Inc (CTRE) -41%

Frequently asked questions

Is Chiron Real Estate Inc (XRN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $90.04 versus a price of $36.12 — about +149% (undervalued). Model-based estimate, not financial advice.
What is the fair value of XRN?
Our 21-model fair value for Chiron Real Estate Inc is $90.04 (as of Jun 25, 2026), built from audited fundamentals. The current price is $36.12.
What is the quality score of XRN?
Chiron Real Estate Inc has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.